Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

被引：10
作者：
Yoon, Esther C. [1 ]
Schwartz, Christopher [1 ]
Brogi, Edi [2 ]
Ventura, Katia [2 ]
Wen, Hannah [2 ]
Darvishian, Farbod [1 ]
机构：
[1] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
来源：
BREAST JOURNAL | 2019年 / 25卷 / 05期
关键词：
21-gene recurrence score assay; American Joint Committee on Cancer; biomarkers; breast cancer; estrogen receptor; human epidermal growth factor receptor 2; OncotypeDx (TM); progesterone receptor; prognosis; staging; DX RECURRENCE SCORE; AMERICAN JOINT COMMITTEE; ESTROGEN-RECEPTOR; VALIDATION; ASSAY; CARCINOMA; RECOMMENDATIONS; EXPRESSION; SOCIETY; PREDICT;
D O I：
10.1111/tbj.13352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The 8th edition of the American Joint Committee on Cancer (AJCC) staging guidelines combine traditional TNM system with biomarkers to reflect our current understanding of tumor biology and targeted therapy. In this study, we investigated the impact of the TNM + Biomarkers staging system and the additive value of Oncotype Dx (TM) genomic profile recurrence score (RS) (TNM + Biomarkers+RS <11) for the staging of breast cancer (BC) using data from two tertiary referral cancer centers. Compared to TNM alone, the TNM + Biomarkers system changed the stage group in 32.7% of BCs (27% downstage, 5.7% upstage). Most (98.3%) of the downstaged BCs were estrogen receptor (ER)+/progesterone receptor (PR)+, whereas 78% of the upstaged BCs were ER-/PR-/human epidermal growth factor receptor 2 (HER2)-. Compared to TNM + Biomarkers staging, the addition of genetic profile data (TNM + Biomarker+RS <11) downstaged only <1% BCs. Our analysis suggests that for T1-T2N0 ER+/HER2- BCs, Oncotype Dx (TM) RS <11 provides added value as a staging parameter only in a very small group of cases compared to TNM + Biomarkers alone.
引用
收藏
页码：829 / 837
页数：9
相关论文
共 43 条
[1]   Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting [J].
Abdel-Rahman, Omar .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) :269-275
[2]   Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? [J].
Allison, K. H. ;
Kandalaft, P. L. ;
Sitlani, C. M. ;
Dintzis, S. M. ;
Gown, A. M. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :413-424
[3]  
[Anonymous], UPDATED AJCC BREAST
[4]  
Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1
[5]   Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists [J].
Badve, Sunil ;
Dabbs, David J. ;
Schnitt, Stuart J. ;
Baehner, Frederick L. ;
Decker, Thomas ;
Eusebi, Vincenzo ;
Fox, Stephen B. ;
Ichihara, Shu ;
Jacquemier, Jocelyne ;
Lakhani, Sunil R. ;
Palacios, Jose ;
Rakha, Emad A. ;
Richardson, Andrea L. ;
Schmitt, Fernando C. ;
Tan, Puay-Hoon ;
Tse, Gary M. ;
Weigelt, Britta ;
Ellis, Ian O. ;
Reis-Filho, Jorge S. .
MODERN PATHOLOGY, 2011, 24 (02) :157-167
[6]   Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer [J].
Bae, Soo Youn ;
Kim, Sangmin ;
Lee, Jun Ho ;
Lee, Hyun-chul ;
Lee, Se Kyung ;
Kil, Won Ho ;
Kim, Seok Won ;
Lee, Jeong Eon ;
Nam, Seok Jin .
BMC CANCER, 2015, 15
[7]   Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma [J].
Bomeisl, Philip E. ;
Thompson, Cheryl L. ;
Harris, Lyndsay N. ;
Gilmore, Hannah L. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) :1546-1549
[8]   The distinctive nature of HER2-positive breast cancers [J].
Burstein, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1652-1654
[9]   Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage [J].
Chen, Lu ;
Linden, Hannah M. ;
Anderson, Benjamin O. ;
Li, Christopher I. .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (03) :609-616
[10]   The new TNM-based staging of breast cancer [J].
Cserni, Gabor ;
Chmielik, Ewa ;
Cserni, Balint ;
Tot, Tibor .
VIRCHOWS ARCHIV, 2018, 472 (05) :697-703
12345